Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary

November 14, 2024

London Stock Exchange GB Health Care Biotechnology earnings 22 min

Earnings Call Speaker Segments

Operator

operator
#1

Hello, and welcome to the conference call covering Palatin's operating results for the first quarter and fiscal year 2025. Right now, everyone attending is in listen-only mode. After the formal presentation, there will be a question-and-answer session. <<operator_script>> Please be aware that this call is being recorded. Before we get to our remarks, I want to note that anything Palatin states that isn't a historical fact could be a forward-looking statement. Such statements rest on assumptions that might or might not turn out to be accurate, and actual results could differ materially from what is anticipated, owing to the various risks and uncertainties covered in the company's latest filings with the Securities and Exchange Commission. As you evaluate these forward-looking statements about Palatin's prospects, please weigh such risks and uncertainties carefully. I'd now like to hand the call to our host, Dr. Carl Spana, Palatin's President and Chief Executive Officer. Please go ahead.

Carl Spana

executive
#2

Thanks. Morning, everyone, and welcome to the Palatin call covering the first quarter of fiscal year 2025. This is Dr. Carl Spana, President and CEO of Palatin. Joining me today is Steve Wills, our Chief Financial Officer and Chief Operating Officer at Palatin. At this point I'll hand things over to Steve, who will walk you through the financial update.

Stephen Wills

executive
#3

Thanks, Carl, and hello everyone. Turning to the fiscal first quarter that closed on September 30, 2024, on the revenue side: after the December 2023 completion of the deal selling Vyleesi's global rights for female sexual dysfunction to Cosette Pharmaceuticals for as much as $171 million, Palatin booked no product sales to pharmacy distributors during that quarter ended September 30, 2024. In the quarter ended September 30, 2023, gross product sales came to $4.6 million, with net product revenue of $2.1 million. On operating expenses: total operating expenses for the quarter ended September 30, 2024 were $7.8 million, versus $8.2 million in the same quarter a year earlier. That decline came primarily from removing selling expenses tied to Vyleesi, partly offset by heavier spending on our MCR programs — MCR meaning Melanocortin receptor. On cash flows: net cash used in operations for the quarter ended September 30, 2024 was $7 million, against roughly $5.9 million of net cash used in operations in the same period of 2023. That rise in net cash used in operations stems mainly from the larger net loss in the period, and secondarily from working capital changes.

Stephen Wills

executive
#4

On the net loss side, for the quarter that closed September 30, 2024, Palatin recorded a net loss of $7.8 million, versus a net loss of $5.2 million during the same period in 2023. The quarter ended September 30, 2024 showed a larger net loss than the quarter ended September 30, 2023, and the main driver was the elimination of Vyleesi net product revenue, which was partly offset by the elimination of Vyleesi selling expenses along with recognition of the change in fair market value of warrant liabilities for the quarter ended September 30, 2023. Turning to cash position, Palatin's cash and cash equivalents stood at $2.4 million as of September 30, 2024, compared with cash and cash equivalents of $9.5 million as of June 30, 2024. In November 2024, Palatin did receive a scheduled $2.5 million deferred payment from Cosette Pharmaceuticals tied to the sale of Vyleesi. Of course, because that payment came in November, it is not reflected in our September 30 cash and cash equivalents balance. As for our go forward operations, future investment and activities are going to be focused and limited to our core programs in obesity. We have retained an investment bank to conduct, explore and evaluate strategic options for our non-obesity programs. At this stage, there is significant interest in and ongoing discussions for our Phase 3 dry eye disease program, our early stage glaucoma and retina development programs and our Phase 2 ulcerative colitis program from multiple parties.

Stephen Wills

executive
#5

And with that, I'll hand things back to Carl.

Carl Spana

executive
#6

Thanks, Steve. I'll walk through the operating update for the quarter now. Right now we're running a Phase 2 trial, BMT-801, that's assessing how safe and effective it is to give the Melanocortin-4 receptor agonist bremelanotide together with tirzepatide — a GLP-1 GFP dual agonist — in patients who have generalized obesity. Beyond safety, the study's primary efficacy endpoint looks at whether combining these two treatments can deliver greater efficacy when it comes to reducing weight. We'll also be evaluating a range of secondary endpoints, including effects on satiety, preservation of lean body mass, and weight loss maintenance. As of October, enrollment for the study is complete, and given how strongly patients demanded to get in and how fast they enrolled, we could grow the study's size from 60 patients to approximately 115. We expect top line results in the first quarter of 2025. Our portfolio for obesity and weight loss management covers both a novel acting, long acting Melanocortin-4 receptor peptide agonist and the orally active MCR4 selective small molecule agonist PL7737. Both of these programs remain on track to enter IND-enabling activities and clinical studies in calendar 2025. Our novel next generation selective MCR-4 compounds show reduced activity at the Melanocortin-1 receptor, which means their potential to cause skin darkening is reduced.

Carl Spana

executive
#7

We think that having little activity or skin darkening, together with dosing once a week or oral dosing, means meaningful gains compared with the Melanocortin treatments the FDA currently approves. More details about our clinical trial are available at clinicaltrials.gov, and our website features recent presentations on our novel next generation MCR-4, Melanocortin-4 receptor selective compounds. For PL8177, our orally selective MCR1 treatment for ulcerative colitis, top line data from the Phase 2 study will come in the first quarter of 2025. Ahead of that data, business development discussions with potential partners have risen significantly, consistent with our present strategy of out licensing this exciting program. And last, for our Phase 2 breakout study of bremelanotide in patients with diabetic kidney disease, we expect to release top-line data this quarter or in the fourth quarter of 2024. Before we move on to take questions, I want to comment on our strategy. By targeting the Melanocortin system, our research team has generated, very productively, multiple exciting development programs in anti-inflammation and ocular diseases, sexual dysfunction and obesity. Discussions senior management has held with the Board of Directors, investors and outside consultants make it clear that, as a small company, we must concentrate our limited resources and efforts in one area in order to succeed long term.

Carl Spana

executive
#8

Like Steve said earlier on this call, our research and development work is going to start concentrating on the MCR-4 obesity assets. In our view, pharmacological obesity treatment sits at the beginning of a multiyear innovation cycle, and its market value will exceed $100 billion each year. The melanocortin system is critically important when it comes to regulating stored energy and food intake. We hold a strong belief that Melanocortin-4 receptor agonists, including the ones we are developing, are going to be an important part of obesity treatment and weight loss management going forward. Palatin has conducted research over a long period aimed at developing Melancortin therapeutics that selectively activate the Melancortin 4 receptor as treatments for obesity and weight loss maintenance. Thanks to extensive experience in designing and developing Melanocortin agonists for treating obesity, including two clinical studies that were completed and published previously, we are well-positioned to lead in developing Melancortin-based therapeutics, weight loss and, importantly, weight loss maintenance. By concentrating our efforts on our MCR-4 obesity and weight loss maintenance, we intend to drive a substantial increase in shareholder value. That said, as Steve noted, focusing our efforts does not mean we think our other assets are worth less.

Carl Spana

executive
#9

On the other hand, we think our ocular assets—led by the PL9643 Phase 3 dry eye disease program and the lead compounds in glaucoma and retinal diseases—hold enormous value and justify ongoing investment. We're pursuing several avenues at once to capture the value of these programs, including possible out licensing to a bigger company, conversations with investors who want to fund further development, and talks with peer companies about potential business combinations. We'll follow comparable strategies with our PL8177 oral inflammatory bowel disease asset and our sexual dysfunction assets as well, so that we can deliver a return to our shareholders. So, Stephen, thank you for joining the call, and we're now going to open the line for questions.

Operator

operator
#10

Thanks a lot. <<operator_script>> Our first question comes from Joe Pantginis at H. C. Wainwright. Joe, your line is open.

Joe Pantginis

analyst
#11

Hey, guys. Appreciate you taking the questions and the details as usual. Just wanted to — just logistically, on the back end of your comments, ask if I heard you correctly. So for the ulcerative colitis program and following the data, did you say that all the options are available, typical partnering that you might engage with discussions, project finance and beyond?

Carl Spana

executive
#12

Right. Specifically, for that single business development involving what's likely a bigger company — since that study started, interest has been really strong. We've got maybe 5 or 6 major firms signed under CDA. And since we expect the data in the first quarter, we've gone back to them and are bringing them up to speed on our status. So we're fairly confident that assuming a favorable result, which we believe is coming, that program will advance toward being out-licensed.

Joe Pantginis

analyst
#13

Understood. And clearly, obesity is the main focus at this point. So, if you don't mind, a few questions. For the 801 study, with data due out next quarter, what would you consider a successful trial? Because obviously you mentioned you'll be examining multiple components — how would that shape your next steps on the combination?

Carl Spana

executive
#14

Let me pull back for a moment and offer a somewhat broader perspective, and after that I'll move into the finer details. At present, the incretins constitute the standard line of therapy for obesity. Those are the drugs you know as Zepbound or Wegovy. Additional versions of those are on the way, yet all of them share a fairly comparable mechanism. They do work, and honestly, some of the newer agents arguably work too well. My view is that over the long run, what will emerge is combination therapy, in which you will need to pair different mechanisms so that the large number of patients with obesity can safely hit their treatment goals. To be clear — even though it does work, I'm not a big fan of these newer agents now arriving that drive 25%, 30% weight loss in six months. That, in my opinion, isn't healthy, and outside of the morbidly obese, it's probably not the right approach. The right approach, I believe, is slower weight loss that combines mechanisms, so that weight loss is prolonged and these patients can reach their weight loss goals.

Carl Spana

executive
#15

Actually, what we know is that existing therapies largely quit working by the time 1 year has passed — they flatten out, they plateau. That means you're going to need additional treatments, such as the melanocortin mechanism, to genuinely extend that weight loss so people can actually hit their weight loss goals. So that's really the origin of why — or the top-line reason — we're pursuing this. To be more specific, we've been conducting pre-clinical research work, and clinical work is also underway at Oklahoma, and both suggest that pairing a melanocortin mechanism with an incretin therapy such as Wegovy or tirzepatide in this case actually improves weight loss. So that's really what we're trying to show here. By putting these two mechanisms together, we can see that one and one hopefully adds up to more than two. Now, this is an exploratory study. It's a first step in that direction. We're not going to claim that we've got all the doses and everything optimized. But I do think that we should see a real increase in weight loss when premelanotide is added to tirzepatide. Beyond that, we'd like to — because of how the study is set up, we will be able to examine things like weight loss maintenance.

Carl Spana

executive
#16

Beyond that, we will also be examining lean muscle mass, which is extremely important these days. As incretins drive weight loss, you start losing more muscle mass than is ideal. I believe this has been documented in the literature, and we have observed pre-clinically that weight loss from the melanocortin mechanism actually preserves lean muscle mass. That is another measure we consider, and it is a very important one. Then, naturally, there is safety — clearly, when combining 2 distinct mechanisms, we want to confirm that no safety signals emerge.

Joe Pantginis

analyst
#17

Thanks, that's quite useful, and I appreciate the specifics. And I suppose, given how quickly things are shifting, you're hearing more firms bring up the weight loss maintenance piece that you just mentioned. So when you think about — and I'm attempting to jump ahead a bit here — when you think about both the MCR-4 long acting peptide approach and the oral small molecule approach, is that aimed at general obesity, weight loss management? And do you see it as possible monotherapies or combination therapies?

Carl Spana

executive
#18

Well, it's sort of a combination of everything mentioned. What I'm getting at is that you obviously began with keeping weight off, which I believe is a very significant matter and one that's growing in significance. I was recently at a BC week, and people are beginning to discuss it. But the advantage — both Lilly and Noble have released their long-term data. And what stands out clearly is that when treatment stops, patients put the weight back on quickly, and the cardiometabolic and other gains that existed because of the treatment and the weight loss vanish. So to truly secure those benefits from the weight loss and treatment, you'll need to stay on treatment over the long term. That will demand different mechanisms, and the Melanocortin system fits that need very well. I won't go into the science, but plenty of solid science backs its role in energy stores and energy balance, and through low dose activation of that system, you likely can assist in sustaining weight loss. Thinking about it more broadly across the general population too, add-on therapy to the incretins certainly is a possibility there, as a potential monotherapy for patients who are failing therapy and dropping off, since they can't tolerate it as they dose escalate and they need to switch to different therapies too.

Carl Spana

executive
#19

There are plenty of possibilities for a solid Melanocortin approach, and I spoke with somebody who functions almost like a utility player, correct? You can deploy it in many different spots to create value when treating these patients, ranging from weight loss maintenance all the way to primary treatment. And that applies to the small molecule and the peptide alike. Each will likely end up serving somewhat distinct patient groups, where their benefit will be greatest, yet both hold value and ought to be advanced.

Joe Pantginis

analyst
#20

That's really useful once more, thank you. And then, I suppose, a final obesity question. Looking at the wider obesity market, and hypothalamic obesity in particular, where do you see your place relative to the other compounds currently in development? Because it appears — particularly with the Melanocortin approaches — that you have wide applicability.

Carl Spana

executive
#21

Sure. So there's clearly a melanocortin product that's approved for various forms of what we refer to as genetic or syndromic obesity—that one is a semilantide. And there's a large trial of it that ought to report out at some point next year in hypothalamic obesity. That's an area we're also assessing, in terms of how we want to compete there. I'd say through the newer compounds as well—setmelanotide is what I'd describe as a first-generation compound, quite similar to our bremelanotide, and it comes with skin darkening plus other side effects you'd probably rather avoid in a long-term obesity therapy. On top of that, it's administered every day. When we consider where we're aiming to take our compounds, we want either a small molecule that's orally active, which is what we've got with PL7737, or a peptide with long-acting duration dosed once weekly, much like the way the ingredients are. And then, with a melanocortin agonist, you'd really want to eliminate the MCR-1. That way you avoid skin darkening. And again, not—plenty of patients don't particularly care about it, but some patients do. So if you're able to remove it, as we have, that's an improvement.

Joe Pantginis

analyst
#22

Thanks for that. So, looking at the whole company story at the moment, things have been pretty dynamic. There are some clear catalysts ahead of us in the first quarter. You were also speaking quite a bit more about the various business development opportunities and strategic options. You brought up different options — whether it's standard BD, project finance, or, I'll add this in too, what you said about project finance perhaps coming from investors, but there are also, say, the various royalty aggregators out there. How would you describe, if you can, the mix of those kinds of financial approaches at present?

Carl Spana

executive
#23

I think we need to view them in a somewhat different light. For our ocular franchise, that is really close to being one of the reasons we're pursuing what we're pursuing — that franchise has essentially reached the stage where it's almost a company in its own right, correct? You have dry eye disease in Phase 3, you have glaucoma, and you have the retinal programs that are ready to go and advance into development. What holds them back is a shortage of investment, since we're a small company. So that truly set things off — Genesis began when we released the Phase 3 data early in the year for the Triadis product, because we really need to push these things forward. They call for far more financial resources than we possess. So in looking at that, everything is on the table. We do have large companies that are very interested in the dry eye disease programs, and then we have glaucoma and the retinal as well. So it may be a mixture. You may see an out licensing of dry eye disease and then a corporate combination of assets for the others that are a little bit earlier, or you may see a split, you may see one front of the eye going one way and the back of the eye glaucoma and retina going to another — different large company.

Carl Spana

executive
#24

One thing Steve has consistently been very clear about is that we want to preserve our optionality and pursue the best transaction for Palatin and shareholders. So we're not going to be locked into saying it must be this or it must be that. It has to be the right transaction, one that offers the best potential return for the company.

Stephen Wills

executive
#25

Jeff, one more thing I’d like to mention: when we state in the press release that there is good interest, significant interest, and continuing talks, those talks involve not only several parties but, as Carl mentioned, several distinct categories of parties, ranging from large pharmaceutical companies to smaller specialty pharmaceutical firms. An asset of theirs combined with ours might produce a two plus two equals five, six, or seven outcome. Yet this interest and these discussions are covered by a CDA, they are taking place in the data room, and they are moving ahead on several fronts. As Nostradamus confirmed, we expect to have multiple deals going forward, and some of them could come as early as the first quarter of next year.

Joe Pantginis

analyst
#26

Everyone, I truly appreciate all the specifics, and I'm especially eager to watch how those strategic options unfold. Many thanks.

Carl Spana

executive
#27

Appreciate the question, Joe.

Operator

operator
#28

Thanks a lot. It looks like we’ve come to the conclusion of the question-and-answer portion. At this point, I’ll turn things back to Carl for any closing comments.

Carl Spana

executive
#29

Thank you. Steve and I want to express our appreciation to everyone for joining us for the first quarter of fiscal year 2025. There is a great deal of excitement on our side about what we have in place. Our interest in the Melanocortin system has been a long-term one, specifically as it relates to obesity and maintaining weight loss. We find ourselves now at a truly excellent moment, when interest in what we are doing is extremely high, and we genuinely possess the right collection of assets to create tremendous value. As usual, additional details are available on our website. It is in fact a quite valuable resource. If you go to the resources section, you will find all of our publications, presentations, and posters that we produce. That material is quite extensive, so further information is always available there. Once again, Steve, myself, and the entire staff here are really, really quite enthusiastic about what lies ahead for the company, and we look forward to continuing to keep all of you updated as we move forward. Thank you, guys, and have a great day, everyone.

Operator

operator
#30

Thanks so much. That brings today's conference to a close. At this point you can hang up your phone lines, and we hope the rest of your day is wonderful. We appreciate you taking part.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.